Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Paclitaxel Oral Solution Plus Fruquintinib Versus Investigator's Choice as Second-Line Treatment for Advanced Gastric Cancer: A Multicenter, Open-Label, Randomized Controlled Trial

NCT07552402 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT07552402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07552402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Paclitaxel Oral Solution Plus Fruquintinib Versus Investigator's Choice as Second-Line Treatment for Advanced Gastric Cancer: A Multicenter, Open-Label, Randomized Controlled Trial
Lead sponsor
Harbin Medical University
Phase
Not applicable
Overall status
Recruiting
Start date
June 10, 2026
Completion date
December 30, 2028
Enrollment
150 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer or gastroesophageal junction adenocarcinoma